首页> 外文期刊>Cytotechnology >Effects of passage number on growth and productivity of hybridoma secreting MRSA anti-PBP2a monoclonal antibodies
【24h】

Effects of passage number on growth and productivity of hybridoma secreting MRSA anti-PBP2a monoclonal antibodies

机译:传代数对分泌MRSA抗PBP2a单克隆抗体的杂交瘤细胞生长和生产力的影响

获取原文
       

摘要

Monoclonal antibodies (mAb) are high added value glycoproteins recommended for immunotherapy, diagnosis, and also for the treatment of bacterial infections resistant to multiple drugs such as Methicillin Resistant Staphylococcus aureus (MRSA). In addition to environmental conditions related to cell cultures, the intrinsic characteristics of hybridoma cells, like the secretion stability of monoclonal antibodies by the cells through successive subcultures, are relevant for the characterization of cell lines related to the productivity of mAb. The rate of mAb production differs significantly between different cell lines and different passage numbers, and it is an important variable in characterization of cell lines. In order to find a more robust, faster-growing, and higher-productivity cell line of hybridoma, cultivations in 24-well plates were performed in different subculture periods, or cell passages (P), of hybridoma cells producing MRSA anti-PBP2a monoclonal antibodies [MRSA-antiPBP2a (mAb)]. The objective of this study was to study the effects of cell growth and production of MRSA-antiPBP2a mAb secreted by murine hybridoma cells grown in different passages as well as determine the which passages the hybridomas can be cultivated without harming their growth and productivity. So, cell growth profiles of hybridomas secreting MRSA-antiPBP2a (mAb) and the production of MRSA-antiPBP2a mAb in different subculture periods or cell passages (P) were studied. Cell growth tests, monoclonal antibody productivity, and metabolite characteristics revealed substantial differences in those cells kept between P10 and P50. Similarities in the secretion of monoclonal antibody, growth, and metabolic profiles, were noted in the MRSA-antiPBP2a mAb producing hybridoma cells kept between P10 and P20. Also, glucose consumption (g/L) and lactate production (g/L) in the latter cell cultures were monitored daily through biochemical analyzer. As of P30, it was observed a 4.4 times reduction in productivity, a 13?% reduction in metabolic yield, and a significant change in cell growth. Secretion of MRSA-antiPBP2a mAb should be obtained through the culture of hybridomas up to P20 in order to keep its stability.
机译:单克隆抗体(mAb)是高附加值的糖蛋白,建议用于免疫治疗,诊断以及对多种药物(如耐甲氧西林金黄色葡萄球菌(MRSA))的细菌感染的治疗。除了与细胞培养有关的环境条件外,杂交瘤细胞的固有特性,例如细胞通过连续继代培养产生的单克隆抗体的分泌稳定性,也与与mAb生产率相关的细胞系表征有关。在不同细胞系和不同传代数之间,mAb的产生速率差异显着,这是表征细胞系的重要变量。为了找到杂交瘤的更强大,生长更快和更高生产率的细胞系,在产生MRSA抗PBP2a单克隆抗体的杂交瘤细胞的不同继代培养期或细胞传代(P)中,在24孔板中进行培养抗体[MRSA-antiPBP2a(mAb)]。这项研究的目的是研究在不同传代中生长的鼠杂交瘤细胞分泌的细胞生长和产生的MRSA-antiPBP2a mAb的影响,并确定可在不损害杂交瘤生长和生产力的情况下培养哪些传代。因此,研究了在不同的继代培养时期或细胞传代(P)中分泌MRSA-antiPBP2a(mAb)的杂交瘤细胞的生长概况以及MRSA-antiPBP2a mAb的产生。细胞生长测试,单克隆抗体生产率和代谢产物特征显示,保留在P10和P50之间的那些细胞存在显着差异。在产生于MRSA-antiPBP2a mAb的杂交瘤细胞中(在P10和P20之间),注意到了单克隆抗体分泌,生长和代谢谱的相似性。另外,通过生化分析仪每天监测后者细胞培养物中的葡萄糖消耗(g / L)和乳酸产生(g / L)。从P30开始,观察到生产率降低了4.4倍,代谢产率降低了13%,并且细胞生长发生了显着变化。 MRSA-antiPBP2a mAb的分泌应通过培养直至P20的杂交瘤来获得,以保持其稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号